|
Impact of infusion timing (IT) on survival outcomes across gastrointestinal (GI) malignancies: A multicenter analysis of circadian rhythm (CR) effects on immune checkpoint inhibitor (ICI) activity. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - Lilly; Natera |
Consulting or Advisory Role - Advanced Accelerator Applications; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genentech/Roche; Incyte; Incyte; Novartis |
Research Funding - AstraZeneca; Bayer |
| |
|
|
Leadership - Mayo Clinic Cancer Center |
Consulting or Advisory Role - Amgen (Inst); Astellas Scientific and Medical Affairs Inc; Astellas Scientific and Medical Affairs Inc; AstraZeneca; AstraZeneca (Inst); beigene; BeiGene (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology; Industry Sponsor (Confidential) (Inst); Industry Sponsor (Confidential) (Inst); Jazz Pharmaceuticals (Inst); LSK Biopharma (Inst); Macrogenics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Zymeworks (Inst) |
Research Funding - Amgen (Inst); BeiGene (Inst); Bristol Myers Squibb Foundation (Inst); CARsgen Therapeutics (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - beigene |
| |
|
Consulting or Advisory Role - Exelixis |
Research Funding - Amgen (Inst); Aminex (Inst); Arcus Biosciences (Inst); Camurus (Inst); RayzeBio (Inst); Viewpoint Molecular Targeting (Inst) |
| |
|
Stock and Other Ownership Interests - Zentalis |
Consulting or Advisory Role - Tempus (Inst) |
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline/Tesaro (Inst); Merck (Inst); Newlink Genetics (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - OncLive/MJH Life Sciences; OncLive/MJH Life Sciences (Inst); Takeda; WebMD/Medscape; WebMD/Medscape (Inst) |
Consulting or Advisory Role - Agenus; Agenus (Inst); Artemida Pharma; Bristol Myers Squibb; Fortvita (Inst); Guardant Health; Incyte (Inst); Taiho Oncology; Taiho Pharmaceutical (Inst); Takeda (Inst); Tempus |
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Artios (Inst); Biomea Fusion (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Cardiff Oncology (Inst); Daiichi Sankyo/Lilly (Inst); HCW Biologics (Inst); Incyte (Inst); Ipsen (Inst); Johnson & Johnson/Janssen (Inst); Kumquat Biosciences (Inst); Natera (Inst); Nouscom (Inst); Novartis (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - GlaxoSmithKline; Incyte; NCCN; Takeda |
Other Relationship - UpToDate |
(OPTIONAL) Uncompensated Relationships - NCCN |
| |
|
Consulting or Advisory Role - Cardiff Oncology (Inst); Xilio Therapeutics (Inst) |
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BioNTech SE (Inst); Cardiff Oncology (Inst); DynamiCure Biotechnology (Inst); Innovent Biologics (Inst); Pfizer (Inst); Qurient Therapeutics (Inst); SparX Biopharmaceutical Corp (Inst); Xilio Therapeutics (Inst); Xilis (Inst) |
Patents, Royalties, Other Intellectual Property - Patent application entitled "DEGRADERS OF SON OF SEVENLESS HOMOLOG 1" was filed with the United States Patent and Trademark Office on 8/11/2023. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Biomea Fusion; Boehringer Ingelheim; Camurus (Inst); Crinetics Pharmaceuticals (Inst); Curium Pharma; Exelixis; Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Perspective Therapeutics (Inst); Tersera; Viewpoint Molecular Targeting (Inst) |
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Perspective Therapeutics (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst) |
(OPTIONAL) Uncompensated Relationships - North American Neuroendocrine Tumor Society |
| |
|
Consulting or Advisory Role - AstraZeneca (Inst); DAVA Oncology (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Ipsen (Inst); QED Therapeutics (Inst); TEMPUS (Inst) |
Speakers' Bureau - DAVA oncology (Inst) |
Research Funding - Exact Sciences |
| |
Lionel Aurelien Kankeu Fonkoua |
Honoraria - Exelixis (Inst); Incyte (Inst); S2N Health (Inst) |
Consulting or Advisory Role - Exelixis (Inst); Incyte (Inst); S2N Health (Inst) |
| |
|
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Basilea (Inst); Biond Biologics (Inst); Celgene (Inst); Eisai (Inst); Halozyme (Inst); Incyte (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Merck Serono (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Qurient (Inst); RedHill Biopharma (Inst); Relay Therapeutics (Inst); Senhwa Biosciences (Inst); SillaJen (Inst); Taiho Pharmaceutical (Inst); ZielBio (Inst) |
| |
|
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab |
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687 |
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis |
| |
|
|
Consulting or Advisory Role - Bayer (Inst); Boehringer Ingelheim (Inst) |
Research Funding - Lilly (Inst); Taiho Oncology (Inst) |